These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 23361053)
1. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer. Ghosh A; Awasthi S; Peterson JR; Hamburger AW Br J Cancer; 2013 Feb; 108(3):557-63. PubMed ID: 23361053 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells. Akinmade D; Talukder AH; Zhang Y; Luo WM; Kumar R; Hamburger AW Br J Cancer; 2008 Mar; 98(6):1132-40. PubMed ID: 18283314 [TBL] [Abstract][Full Text] [Related]
3. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells. Lu Y; Zhou H; Chen W; Zhang Y; Hamburger AW Breast Cancer Res Treat; 2011 Feb; 126(1):27-36. PubMed ID: 20379846 [TBL] [Abstract][Full Text] [Related]
4. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Gonzalez N; Cardama GA; Comin MJ; Segatori VI; Pifano M; Alonso DF; Gomez DE; Menna PL Cell Signal; 2017 Jan; 30():154-161. PubMed ID: 27939839 [TBL] [Abstract][Full Text] [Related]
6. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121 [TBL] [Abstract][Full Text] [Related]
8. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231 [TBL] [Abstract][Full Text] [Related]
9. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868 [TBL] [Abstract][Full Text] [Related]
10. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells. Awasthi S; Ezelle H; Hassel BA; Hamburger AW Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of tyrosine 285 of PAK1 facilitates βPIX/GIT1 binding and adhesion turnover. Hammer A; Oladimeji P; De Las Casas LE; Diakonova M FASEB J; 2015 Mar; 29(3):943-59. PubMed ID: 25466889 [TBL] [Abstract][Full Text] [Related]
12. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946 [TBL] [Abstract][Full Text] [Related]
13. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Hirokawa Y; Arnold M; Nakajima H; Zalcberg J; Maruta H Cancer Biol Ther; 2005 Sep; 4(9):956-60. PubMed ID: 16082189 [TBL] [Abstract][Full Text] [Related]
14. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049 [TBL] [Abstract][Full Text] [Related]
15. [The role of protein kinase PAK1 in the regulation of estrogen-independent growth of breast cancer]. Avilova EA; Andreeva OE; Shatskaia VA; Krasil'nikov MA Biomed Khim; 2014; 60(3):322-31. PubMed ID: 25019394 [TBL] [Abstract][Full Text] [Related]
16. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559 [TBL] [Abstract][Full Text] [Related]
17. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392 [TBL] [Abstract][Full Text] [Related]
18. Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation. Kwon NH; Lee MR; Kong J; Park SK; Hwang BJ; Kim BG; Lee ES; Moon HG; Kim S RNA Biol; 2018; 15(4-5):635-648. PubMed ID: 28816616 [TBL] [Abstract][Full Text] [Related]
19. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
20. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro]. Zhang QY; Zhao WH; Kang XM Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):826-30. PubMed ID: 17416003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]